Exelixis Charter Oak Partner

Connecticut Oncology Association

Home

About Us

Officers

Contact Us

Events

Corporate Partners

Membership

Member Application

Resources

Members Only

Corporate Sites

https://www.exelixis.com/

Our Medicines Site

Contact for CT:

Paula Belekewicz

Professional Territory Manager

860-214-6669

pbelekewicz@exelixis.com

Important News and Information

03/26/2025 Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

02/15/2025 Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025

Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer 12/04/2023

Exelixis announces first 100 patients enrolled in Phase 3 02/25/2020

Connecticut Oncology Association (CtOA)

c/o Dawn Holcombe

33 Woodmar Circle
South Windsor, CT 06074
(860) 305-4510

Website design by Sister Webs Design Studio, where 5% of profits are donated to women's cancer funds

Powered by Wild Apricot Membership Software